ECSP22083904A - Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso - Google Patents

Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso

Info

Publication number
ECSP22083904A
ECSP22083904A ECSENADI202283904A ECDI202283904A ECSP22083904A EC SP22083904 A ECSP22083904 A EC SP22083904A EC SENADI202283904 A ECSENADI202283904 A EC SENADI202283904A EC DI202283904 A ECDI202283904 A EC DI202283904A EC SP22083904 A ECSP22083904 A EC SP22083904A
Authority
EC
Ecuador
Prior art keywords
compounds
preparation
methods
pharmaceutical compositions
pharmaceutically acceptable
Prior art date
Application number
ECSENADI202283904A
Other languages
English (en)
Inventor
Bingcan Liu
Patrick Beaulieu
Alexander Perryman
Janek Szychowski
Frédéric Vallée
Robert Papp
Jean-François Truchon
Evelyne Dietrich
Original Assignee
Repare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repare Therapeutics Inc filed Critical Repare Therapeutics Inc
Publication of ECSP22083904A publication Critical patent/ECSP22083904A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos y sales farmacéuticamente aceptables de estos que se pueden usar en el tratamiento de sujetos que los necesitan. Los compuestos descritos en el presente documento pueden ser inhibidores de la cinasa inhibidora de cdc2 específica de treonina y tirosina (Myt1). También se describen composiciones farmacéuticas que contienen los compuestos o sales farmacéuticamente aceptables de estos y métodos para su preparación y uso.
ECSENADI202283904A 2020-04-01 2022-10-27 Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso ECSP22083904A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063003745P 2020-04-01 2020-04-01

Publications (1)

Publication Number Publication Date
ECSP22083904A true ECSP22083904A (es) 2022-11-30

Family

ID=77927736

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202283904A ECSP22083904A (es) 2020-04-01 2022-10-27 Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso

Country Status (25)

Country Link
US (1) US20230151014A1 (es)
EP (1) EP4126879B1 (es)
JP (2) JP7714570B2 (es)
KR (1) KR102995398B1 (es)
CN (1) CN115916783A (es)
AU (1) AU2021250744B2 (es)
BR (1) BR112022019611A2 (es)
CA (1) CA3177200A1 (es)
CO (1) CO2022015638A2 (es)
CR (1) CR20220558A (es)
DK (1) DK4126879T3 (es)
EC (1) ECSP22083904A (es)
ES (1) ES3067113T3 (es)
FI (1) FI4126879T3 (es)
HR (1) HRP20260460T1 (es)
IL (1) IL296934B2 (es)
LT (1) LT4126879T (es)
MA (1) MA59217B1 (es)
MX (1) MX2022012178A (es)
PL (1) PL4126879T3 (es)
PT (1) PT4126879T (es)
RS (1) RS67991B1 (es)
SI (1) SI4126879T1 (es)
SM (1) SMT202600173T1 (es)
WO (1) WO2021195781A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115811976A (zh) * 2020-04-01 2023-03-17 修复治疗公司 使用myt1抑制剂的方法
MX2023003677A (es) * 2020-09-30 2023-06-22 Fl2022 001 Inc Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
US20240207300A1 (en) * 2021-04-07 2024-06-27 Repare Therapeutics Inc. Combination therapies including myt1 inhibitors
US12435090B2 (en) 2021-10-04 2025-10-07 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
US20250145624A1 (en) * 2022-02-18 2025-05-08 Insilico Medicine Ip Limited Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
WO2023155870A1 (en) * 2022-02-18 2023-08-24 Insilico Medicine Ip Limited Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
US20250197405A1 (en) * 2022-03-15 2025-06-19 Insilico Medicine Ip Limited Heteroaromatic compounds as pkmyt1 inhibitors and use thereof
CN119156388A (zh) * 2022-04-15 2024-12-17 海南先声再明医药股份有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂
US20250304537A1 (en) * 2022-05-18 2025-10-02 Repare Therapeutics Inc. Heteroarenes, pharmaceutical compositions containing the same, and methods of using the same
WO2023249563A1 (en) * 2022-06-23 2023-12-28 Engine Biosciences Pte. Ltd. Compounds and method for pkmyt1 inhibition
EP4556474A1 (en) 2022-07-12 2025-05-21 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Compounds as myt1 inhibitors
CN119731177B (zh) * 2022-08-24 2026-01-30 北京丹擎医药科技有限公司 三环杂环衍生物及其组合物和应用
JPWO2024048687A1 (es) 2022-08-31 2024-03-07
WO2024061343A1 (zh) * 2022-09-23 2024-03-28 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂及其应用
WO2024104282A1 (zh) * 2022-11-14 2024-05-23 捷思英达控股有限公司 一种1H-吡咯并[2,3-b]吡啶衍生物、其制备方法及其在医药上的应用
JP2025538617A (ja) * 2022-11-25 2025-11-28 上海齊魯制藥研究中心有限公司 Ｐｋｍｙｔ１阻害剤、製造方法、医薬組成物及びその使用
EP4638449A1 (en) * 2022-12-22 2025-10-29 Repare Therapeutics Inc. Methods of making 2-amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6- dimethyl-1h-pyrrolo-[2,3-b]pyridine-3-carboxamide, a myt1 inhibitor
CN120641415A (zh) * 2023-01-20 2025-09-12 杭州英创医药科技有限公司 作为pkmyt1抑制剂的化合物
WO2024166131A1 (en) 2023-02-09 2024-08-15 Satyarx Pharma Innovations Private Limited Heteroaryl compounds as pkmyt1 inhibitors
WO2024179948A1 (en) * 2023-02-28 2024-09-06 F. Hoffmann-La Roche Ag Indazole compounds as pkmyt1 kinase inhibitors
CN121002026A (zh) 2023-04-19 2025-11-21 赛诺菲 吡咯并吡嗪化合物、其制备及其治疗用途
JP2026516824A (ja) 2023-04-28 2026-05-26 サノフイ ピリドイミダゾロン化合物、その調製物及びその治療的使用
WO2024222899A1 (zh) * 2023-04-28 2024-10-31 海南先声再明医药股份有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂及其应用
WO2024252276A1 (en) * 2023-06-05 2024-12-12 Astrazeneca Ab Pyrrolopyrimidine carboxamides
CN121358735A (zh) * 2023-07-04 2026-01-16 杭州领业医药科技有限公司 Rp-6306的晶型及其制备方法和用途
WO2025007784A1 (zh) * 2023-07-06 2025-01-09 四川科伦博泰生物医药股份有限公司 杂芳环化合物、药物组合物及其制备方法和用途
WO2025040014A1 (zh) * 2023-08-18 2025-02-27 英矽智能科技知识产权有限公司 并环化合物及其制备方法和用途
CN121712774A (zh) * 2023-08-23 2026-03-20 英矽智能科技知识产权有限公司 靶向pkmyt1的双官能化合物和使用方法
EP4777102A1 (en) 2023-09-14 2026-07-22 Debiopharm International SA Combination of a wee1 inhibitor and a pkmyt1 inhibitor
WO2025066504A1 (en) * 2023-09-28 2025-04-03 Laekna Therapeutics Shanghai Co., Ltd. Bicyclic heteroaromatic compounds and their use as pkmyt1 inhibitors
IL327457A (en) * 2023-10-02 2026-05-01 Repare Therapeutics Inc MYT1 inhibitors for the treatment of cancers containing mutations resulting from replication checkpoints
WO2025092773A1 (zh) * 2023-10-31 2025-05-08 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
WO2025119300A1 (zh) * 2023-12-08 2025-06-12 广东东阳光药业股份有限公司 Myt1激酶抑制剂化合物、其药物组合物及其用途
WO2025140592A1 (zh) * 2023-12-29 2025-07-03 华润医药研究院（深圳）有限公司 含氮杂环类化合物及其制备方法和医药用途
KR102981776B1 (ko) 2024-01-17 2026-06-24 성균관대학교산학협력단 회전 장애 이성질체를 포함하는 신규한 n-/2-/3-아릴인돌 유도체 화합물 및 이의 제조 방법
CN120365270A (zh) * 2024-01-23 2025-07-25 杭州中美华东制药有限公司 具有pkmyt1抑制作用的化合物
WO2025169150A1 (en) * 2024-02-09 2025-08-14 Repare Therapeutics Inc. Crystalline forms, crystalline salt forms, compositions containing the same, and methods of using the same
WO2025195505A1 (zh) * 2024-03-22 2025-09-25 海南先声再明医药股份有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂化合物及其应用
WO2025242167A1 (zh) * 2024-05-23 2025-11-27 齐鲁制药有限公司 Pkmyt1抑制剂的多晶型、其制备方法及其应用
WO2026017827A1 (en) * 2024-07-18 2026-01-22 Astrazeneca Ab Carboxamide compounds as pkmyt1 inhibitors
WO2026054021A1 (ja) * 2024-09-05 2026-03-12 中外製薬株式会社 Ｍｙｔ１阻害活性を有する含窒素複素環化合物の結晶
WO2026057598A1 (en) * 2024-09-10 2026-03-19 My-T Bio Limited Therapeutic compounds as pkmyt1 inhibitors and their use
NL2039212B1 (en) 2024-12-02 2026-06-23 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Mitotic cell phase enrichment and ionizing radiation
WO2026125935A1 (en) * 2024-12-09 2026-06-18 Repare Therapeutics Inc. Methods of treating cancers having fbxw7 mutations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033842A1 (en) * 1998-12-07 2000-06-15 Smithkline Beecham Corporation Myt1 kinase inhibitors
CO5261594A1 (es) * 2000-03-02 2003-03-31 Smithkline Beecham Corp Inhibidores de myt1 cinasa
WO2015073528A1 (en) * 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
ES2774177T3 (es) * 2014-09-15 2020-07-17 Plexxikon Inc Compuestos heterocíclicos y usos de estos

Also Published As

Publication number Publication date
SMT202600173T1 (it) 2026-05-12
LT4126879T (lt) 2026-04-27
SI4126879T1 (sl) 2026-06-30
AU2021250744A1 (en) 2022-11-17
HRP20260460T1 (hr) 2026-05-22
IL296934B1 (en) 2026-01-01
CO2022015638A2 (es) 2022-11-18
ES3067113T3 (en) 2026-05-19
FI4126879T3 (fi) 2026-04-01
EP4126879B1 (en) 2026-01-21
KR102995398B1 (ko) 2026-07-27
IL296934B2 (en) 2026-05-01
CR20220558A (es) 2022-12-12
WO2021195781A1 (en) 2021-10-07
RS67991B1 (sr) 2026-05-29
MX2022012178A (es) 2022-12-08
CA3177200A1 (en) 2021-10-07
PL4126879T3 (pl) 2026-05-25
AU2021250744B2 (en) 2026-08-13
EP4126879A1 (en) 2023-02-08
JP2025142057A (ja) 2025-09-29
JP7714570B2 (ja) 2025-07-29
JP2023521633A (ja) 2023-05-25
CN115916783A (zh) 2023-04-04
US20230151014A1 (en) 2023-05-18
KR20230011279A (ko) 2023-01-20
PT4126879T (pt) 2026-04-07
IL296934A (en) 2022-12-01
DK4126879T3 (da) 2026-04-13
BR112022019611A2 (pt) 2022-11-29
EP4126879A4 (en) 2024-04-10
MA59217B1 (fr) 2026-05-26

Similar Documents

Publication Publication Date Title
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
CO2026004964A2 (es) Moduladores de kras
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
BR112022007612A2 (pt) Inibidores de raf quinases
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2022000339A1 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
CL2023003965A1 (es) Inhibidores cdk2.
DOP2023000145A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2024015820A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
CO2024015816A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
MX2025014135A (es) Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos
CO2019012571A2 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
MX2017009643A (es) Composiciones y métodos de uso de inhibidores de tirosina quinasa.
CO2024009144A2 (es) Inhibidores de cinasa met
MX2023014466A (es) Derivados de piridopirimidina útiles como inhibidores de cinasa wee1.
MX2023015436A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
MX2024007240A (es) Moduladores de proteina quinasa asociada a rho (rock).
MX2024010321A (es) Inhibidores de la quinasa tipo polo 4 (plk4), composiciones farmaceuticas, metodos de preparacion y usos de los mismos